Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Invested Capital: 2019-2025

Historic Invested Capital for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $264.6 million.

  • Pharming Group N.V's Invested Capital rose 17.21% to $264.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.6 million, marking a year-over-year increase of 17.21%. This contributed to the annual value of $221.1 million for FY2024, which is 1.04% up from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's Invested Capital is $264.6 million, which was up 10.48% from $239.6 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Invested Capital high stood at $264.6 million for Q3 2025, and its period low was $200,254 during Q3 2022.
  • Over the past 3 years, Pharming Group N.V's median Invested Capital value was $218.8 million (recorded in 2023), while the average stood at $220.0 million.
  • Per our database at Business Quant, Pharming Group N.V's Invested Capital tumbled by 99.90% in 2022 and then skyrocketed by 104,737.86% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Invested Capital stood at $192.9 million in 2021, then grew by 6.08% to $204.6 million in 2022, then rose by 6.91% to $218.8 million in 2023, then climbed by 1.04% to $221.1 million in 2024, then grew by 17.21% to $264.6 million in 2025.
  • Its last three reported values are $264.6 million in Q3 2025, $239.6 million for Q2 2025, and $214.0 million during Q1 2025.